Hansoh Pharmaceutical Group Company Limited: Lung Neoplasms trials

The registry lists 11 Lung Neoplasms studies with Hansoh Pharmaceutical Group Company Limited as lead sponsor. 7 are open to participants now and 1 have results posted.

Phase 1 5Phase 2 4Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCRecruitingNCT07645222Phase 1
• A Phase Ib Study of HS-10504 Combined Therapy in NSCLCNot yet recruitingNCT07414953Phase 1
• A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLCRecruitingNCT06926413Phase 1
• A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung CancerNot yet recruitingNCT06526624Phase 3
• A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerRecruitingNCT06147570Phase 2
• Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung CancerRecruitingNCT05435274Phase 1/2
• A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerRecruitingNCT04951635Phase 3
• A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLCStatus unknownNCT02981108Phase 1/2Results posted
• ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung CancerWithdrawnNCT06052423Phase 2
• Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsActive, not recruitingNCT04923906Phase 3
• Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive MutationsActive, not recruitingNCT04687241Phase 3